{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mycophenolate+%28standard+GVHD+prophylaxis%29", "query": { "intervention": "mycophenolate (standard GVHD prophylaxis)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mycophenolate+%28standard+GVHD+prophylaxis%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T05:34:27.202Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02782546", "title": "Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Graft cell infusion", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "CIML NK cell infusion", "type": "PROCEDURE" }, { "name": "ALT-803", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2017-01-30", "completion_date": "2028-02-13", "has_results": true, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-28T05:34:27.202Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02782546" }, { "nct_id": "NCT01917708", "title": "Bone Marrow Transplant With Abatacept for Non-Malignant Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hurler Syndrome", "Fanconi Anemia", "Glanzmann Thrombasthenia", "Wiskott-Aldrich Syndrome", "Chronic Granulomatous Disease", "Severe Congenital Neutropenia", "Leukocyte Adhesion Deficiency", "Shwachman-Diamond Syndrome", "Diamond-Blackfan Anemia", "Dyskeratosis-congenita", "Chediak-Higashi Syndrome", "Severe Aplastic Anemia", "Thalassemia Major", "Hemophagocytic Lymphohistiocytosis", "Sickle Cell Disease" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 10, "start_date": "2014-01", "completion_date": "2019-09-19", "has_results": false, "last_update_posted_date": "2019-12-26", "last_synced_at": "2026-09-28T05:34:27.202Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01917708" }, { "nct_id": "NCT06731504", "title": "HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hematologic Malignancy" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-11-12", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-09-28T05:34:27.202Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06731504" }, { "nct_id": "NCT05436418", "title": "The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Peripheral Blood Stem Cell Transplantation", "Hematopoietic Stem Cell Transplantation" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mycophenolate Mofeti", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 260, "start_date": "2022-11-18", "completion_date": "2028-06-25", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-28T05:34:27.202Z", "location_count": 2, "location_summary": "Duarte, California • Bethesda, Maryland", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05436418" }, { "nct_id": "NCT03983850", "title": "Optimizing PTCy Dose and Timing", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "Hematologic Neoplasms" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 105, "start_date": "2019-07-09", "completion_date": "2026-10-26", "has_results": false, "last_update_posted_date": "2025-12-26", "last_synced_at": "2026-09-28T05:34:27.202Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03983850" }, { "nct_id": "NCT01954784", "title": "Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Multiple Myeloma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-10-07", "completion_date": "2017-01-30", "has_results": false, "last_update_posted_date": "2017-02-17", "last_synced_at": "2026-09-28T05:34:27.202Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01954784" }, { "nct_id": "NCT00810602", "title": "Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancies", "Graft vs Host Disease" ], "interventions": [ { "name": "reduced intensity, related donor stem cell transplant", "type": "PROCEDURE" }, { "name": "tacrolimus (standard GVHD prophylaxis)", "type": "DRUG" }, { "name": "mycophenolate (standard GVHD prophylaxis)", "type": "DRUG" }, { "name": "vorinostat", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Pavan Reddy, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2009-01", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2014-04-11", "last_synced_at": "2026-09-28T05:34:27.202Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • St Louis, Missouri", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00810602" }, { "nct_id": "NCT00709592", "title": "Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Leukemia", "Multiple Myeloma", "Acute Myeloid Leukemia", "Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Thymoglobulin", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Allogeneic PBSCT or BMT", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "PROCEDURE", "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 42, "start_date": "2008-07-21", "completion_date": "2017-06-28", "has_results": true, "last_update_posted_date": "2018-11-09", "last_synced_at": "2026-09-28T05:34:27.202Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00709592" }, { "nct_id": "NCT03842696", "title": "Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Diseases", "Acute Leukemia in Remission", "Chronic Myelogenous Leukemia - Chronic Phase", "Chronic Myelogenous Leukemia, Accelerated Phase", "Chronic Myelogenous Leukemia, Blastic Phase", "Myelodysplastic Syndromes", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Diffuse Large B Cell Lymphoma", "Non Hodgkin Lymphoma", "Graft Vs Host Disease", "Graft-versus-host-disease" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "Blood and Marrow Transplant (BMT)", "type": "PROCEDURE" }, { "name": "Tacrolimus (or cyclosporine)", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 43, "start_date": "2020-02-04", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-09-28T05:34:27.202Z", "location_count": 7, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03842696" }, { "nct_id": "NCT04262843", "title": "Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "High Risk Myelodysplastic Syndrome", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Granulocyte Colony-Stimulating Factor", "type": "BIOLOGICAL" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "12 Years to 60 Years" }, "enrollment_count": 33, "start_date": "2020-02-07", "completion_date": "2027-05-11", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-28T05:34:27.202Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04262843" } ] }